AI Article Synopsis

  • The study evaluated the protective effect of remote ischemic postconditioning (RIPostC) on kidney function and complications after living donor liver transplants.
  • Patients were divided into RIPostC and control groups, with the RIPostC group undergoing cycles of ischemia and reperfusion on an arm after liver reperfusion.
  • Results showed that while RIPostC reduced the incidence of acute kidney injury (AKI) from 72% to 38%, there were no significant differences in graft function or other clinical outcomes like complication rates and length of hospital stay.

Article Abstract

The aim of this study was to evaluate the protective effect of remote ischemic postconditioning (RIPostC) on graft function and acute kidney injury (AKI) after living donor liver transplantation (LT). Recipients undergoing elective living donor LT were randomly assigned to either the RIPostC group or the control group. Immediately after reperfusion, 4 cycles of ischemia and reperfusion lasting for 5 minutes each were performed on 1 upper limb in the RIPostC group. Graft function was assessed through evaluations of the serum levels of total bilirubin and liver enzymes and the prothrombin time for 28 days after surgery. The incidence of AKI, as defined by the Risk, Injury, Failure, Loss, and End-Stage Kidney Disease classification, was evaluated within 28 days of the operation. In addition, the incidences of graft dysfunction, acute cellular rejection, and major complications; the 1-, 3-, and 6-month mortality rates; the length of stay in the intensive care unit; and the length of hospital stay were also investigated. In all, 78 patients were enrolled in the analysis (n = 39 in each group). No differences in graft function or clinical outcomes were observed between the groups. The incidences of postoperative AKI were 38% (n = 15) in the RIPostC group and 72% (n = 28) in the control group (P = 0.006). Despite no improvements in postoperative graft function, RIPostC decreased the incidence of postoperative AKI after living donor LT in this study. However, no other clinical benefits with respect to the complication rate, length of hospital stay, or short-term mortality rate were observed. Thus, further studies will be needed to evaluate the clinical efficacy of RIPostC in LT fully.

Download full-text PDF

Source
http://dx.doi.org/10.1002/lt.23960DOI Listing

Publication Analysis

Top Keywords

living donor
16
graft function
16
ripostc group
12
remote ischemic
8
ischemic postconditioning
8
donor liver
8
liver transplantation
8
aki living
8
control group
8
length hospital
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!